Vancouver, British Columbia – June 27, 2012 – Sirona Biochem Corp. (TSX-V: SBM, OTC: SRBCF, Frankfurt: ZSB), announced today it has retained Bloom Burton and Co., Canada’s largest and most active healthcare-specialized investment banking group. Bloom Burton and Sirona Biochem’s leadership teams will develop a strategic plan to expand Sirona’s proprietary carbohydrate chemistry platform into new therapeutic areas complementing Sirona’s current SGLT inhibitor program in diabetes.
“We are very pleased that Bloom Burton shares Sirona’s vision for the potential of our scientific platform and excited they have agreed to help us evaluate and select the best development opportunities to advance,” said Dr. Howard Verrico, President and CEO of Sirona Biochem. “Bloom Burton is one of Canada’s most respected healthcare investment banking firms and we are confident that their research capabilities, capital markets expertise and insight into the pharmaceutical industry’s development and partnering priorities will maximize Sirona’s probability of success,” Dr. Verrico added.
About Bloom Burton
Bloom Burton & Co. is Canada’s largest and most active healthcare-specialized investment banking group. Bloom Burton’s team of healthcare specialists merge scientific, medical, clinical, intellectual property and commercial expertise with an understanding of the capital markets, to advise and raise capital for private and public companies. Bloom Burton partners with a variety of companies; from start-up through commercialization, and with those engaged in biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, life science tools, animal health, nutrition and wellness, and agricultural/industrial biotechnology. For more information, visit www.bloomburton.com.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.